Insights

Read our independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and culture.

Our work is reader-supported. Sign up to our free or paid plans here.

The latest

Pα+ Psychedelic Patent Analysis: April 2024

A CaaMTech & ASRI Collaboration • GH Research & Beckley Psytech: An Update • CaaMTech Grows Tryptamine Patent Portfolio • Atai Sees Two New Allowances to Support DMT Program • Browse the Interactive Psychedelics Patent Database for April 2024

California’s Latest Psychedelics Bill Dies in Committee

SB 1012, which would have established regulated, licensed psychedelic services in the state, has fallen victim to ‘suspense day’, where the state’s appropriations committees cull bills en masse. But the bill’s key sponsor, Senator Scott Wiener, has been working for four years to pass psychedelic policy reform in the state; and he’s unlikely to stop now.

The Library

Through our years of reporting we have covered many of the topics we believe to be important to the present and future of the psychedelics space, broadly defined. However, much of this commentary is scattered across Bulletins, deep dives, special reports and year-end reviews.

The Library provides digestible explainers on salient topics across psychedelic drug development, policy and business: from basic explainers such as “what is psychedelic-assisted therapy?” through to more complex matters such as REMS programs and bifurcated scheduling.

It’s exclusively available to our Pα+ subscribers, with new content added regularly.

Pα+ Library: Bifurcated Scheduling

Pα+ Library: we introduce some of the key concepts in the matter of bifurcated scheduling; a process by which an approved drug product may be placed in a different schedule to the substance itself. As we discuss in this piece, this could have significant repercussions for psychedelic research, legality, and even taxes.

Pα+ Library: Psychedelic REMS

Pα+ Library: we sketch out what a psychedelic REMS might look like, highlighting how these programs could have an outsized impact on the post-approval delivery and accessibility of these treatments.

The Psychedelic News Feed Archives

Archived versions of our Psychedelic News Feed.